ArticleOdontology2026
VNN1, upregulated by FOXA1, suppresses osteogenic differentiation and promotes inflammation in LPS-induced periodontal ligament stem cells.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Periodontal ligament stem cells (PDLSCs) possess osteogenic differentiation potential. Inflammatory microenvironments impair PDLSC function under periodontitis. Vanin-1 (VNN1) is upregulated in periodontitis gingival tissues and correlates with disease severity. This study investigated the precise role of VNN1 in periodontitis pathogenesis. Human PDLSCs (hPDLSCs) were stimulated with lipopolysaccharide (LPS) to mimic an inflammatory model. Osteogenic differentiation was assessed by alkaline phosphatase (ALP) and Alizarin Red S (ARS) staining. Expression analysis was performed by quantitative PCR and immunoblot analysis. ROS amount detection was conducted using an assay kit. IL-1β, IL-6, and TNF-α secretion levels were measured by ELISA. The binding of forkhead box A1 (FOXA1) to the VNN1 promoter region was predicted by the JASPAR tool and confirmed by chromatin immunoprecipitation (ChIP) assay. VNN1 and FOXA1 levels were increased in diseased gingival tissues of periodontitis patients and LPS-challenged hPDLSCs. Functionally, depletion of VNN1 attenuated inflammation and enhanced osteogenic differentiation in LPS-stimulated hPDLSCs. Mechanistically, FOXA1 positively regulated VNN1 expression by binding to the VNN1 promoter region. Moreover, VNN1 re-expression reversed the anti-inflammatory and pro-osteogenic effects of FOXA1 silencing in LPS-challenged hPDLSCs. Our study identifies the FOXA1-VNN1 axis as a novel regulator that links inflammation to impaired osteogenesis in hPDLSCs under LPS inflammatory conditions.
Indexed as
Identifiers
41389271What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.